ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 568

Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility

Farhan Syed1, Kassel Fotinos-Hoyer 2, Michael O'Connor 3, Maureen Li 3, Bryan Hermannsson 2, Nicholas Enus 3, Sayali Karve 3, Manish Sharma 4, Gabriele Pradella 3, Robert B.M. Landewé 5, Xenofon Baraliakos 6 and Sarah Warner 3, 1Parexel, Billerica, MA, 2Parexel, Berlin, Germany, 3Parexel, Billerica, 4Parexel, Hyderabad, India, 5Amsterdam University Medical Center, Amsterdam, Netherlands, 6Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, classification criteria and joint, Imaging, radiography

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Axial spondyloarthritis (axSpA) is typically radiographically confirmed on the sacroiliac joint (SIJ) as assessed by the modified New York (mNY) criteria. In clinical trials, the mNY criteria is used to support determination of subject eligibility for study enrollment. Thus, it is important to analyze the mNY scores most likely to result in disagreement between reviewers and to better understand the impact on enrollment of the target axSpA population.

Methods: Data from central independent review of anterior-posterior (AP) pelvis radiographs in a double read model with adjudication for a total of 1,648 subjects from 3 clinical trials (phases 2 and 3) was analyzed for mNY +/- and individual left (L) and right (R) SIJ score discordance. The mNY scores were categorized per joint (R and L) as follows: 1) independent reviewers agreed on SIJ scores, 2) independent reviewers did not agree on individual joint scores, but mNY +/- was not impacted, and 3) independent reviewers did not agree and mNY +/- was impacted (i.e., adjudication triggered). To identify the score combinations which most often resulted in mNY +/- adjudication discrepancy, the frequency of each combination of scores that led to a discrepancy in categories 2 and 3 was determined.

Results: In 69% of the cases with individual score discrepancies per joint (R or L), the mNY assessment was not impacted; whereas, in 31% of these cases, adjudication was triggered (i.e., the mNY assessment was impacted by the R/L score discrepancy; Fig 1a). The score combinations most often associated with at least one joint for a timepoint where adjudication was triggered were: 1 vs. 2, 2 vs. 3, and 1 vs. 3. The score combination most often discrepant, but did not impact the mNY assessment (i.e., did not trigger adjudication) was 0 vs. 1. Overall, the score of 2 was associated with the most ambiguity.

Conclusion: Discrepancies in SIJ scores per joint (R and L) were not significant in approximately 2 out of 3 (69%) of the cases, considering impact on subject population enrollment. However, in approximately 1 out of 3 (31%) of the cases, the SIJ score discrepancies were associated with a disagreement in subject eligibility for study enrollment resulting in an adjudication.

Based on the data presented (Fig 1), a score of 2 was the most frequently involved score in inter-reader 1-step discordance. This may be related to the definition of a score of 2, which is open to a wider scope of interpretation. These results support the use of a double read and adjudication model for eligibility in clinical trials and potential use of other non-radiographic assessments (e.g. MRI) to improve accuracy of classification and appropriate inclusion of subjects into axSpA clinical trials.

Breakdown of Data from 1,648 subjects -1,243: Evaluable with at least one discrepant joint; 18: Not Evaluable; 8: Incomplete; and 379: no discrepancy-


Disclosure: F. Syed, None; K. Fotinos-Hoyer, None; M. O'Connor, None; M. Li, None; B. Hermannsson, None; N. Enus, None; S. Karve, None; M. Sharma, None; G. Pradella, None; R. Landewé, Abbott, 2, 5, 8, Abbott, Amgen, Bristol-Myers Squibb, Centocor, Merck, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 8, Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 2, AbbVie, 5, Abbvie, 5, 8, AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Centocor, GSK, Novartis, Merck, Pfizer, Roche, Schering- Plough, UCB, Wyeth, 5, Ablynx, 5, Amgen, 2, 5, 8, AstraZeneca, 5, BMS, 5, 8, Bristol Myers Squibb, 5, 8, Bristol-Myers Squibb, 5, Celgene, 5, 8, Centocor, 2, 5, 8, Director of Rheumatology Consultancy BV, which is a registered company under Dutch law, 6, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Eli-Lilly, 5, 8, Galapagos, 5, 8, Gilead, 5, 8, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, 8, Janssen, 5, 8, Merck, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Rheumatology bv, 4, Rheumatology Consultancy BV, 9, Roche, 2, 5, 8, Schering-Plough, 2, 5, 8, UCB, 5, 8, UCB Pharma, 2, 5, 8, Wyeth, 2, 5, 8; X. Baraliakos, AbbVie, 2, 4, 5, 8, Biocad, 2, 5, Bristol-Myers Squibb, 2, 4, 5, 8, Celgene, 2, 5, 8, Chugai, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, 8, Janssen, 2, 5, 8, Lilly, 2, 5, 8, MSD, 2, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, UCB, 2, 5, 8; S. Warner, None.

To cite this abstract in AMA style:

Syed F, Fotinos-Hoyer K, O'Connor M, Li M, Hermannsson B, Enus N, Karve S, Sharma M, Pradella G, Landewé R, Baraliakos X, Warner S. Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/understanding-mny-radiograph-score-discordance-in-axial-spondyloarthritis-clinical-trials-using-imaging-criteria-for-subject-eligibility/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/understanding-mny-radiograph-score-discordance-in-axial-spondyloarthritis-clinical-trials-using-imaging-criteria-for-subject-eligibility/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology